Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...

For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...